Dendreon Appoints Richard Ranieri as Senior Vice President of Human Resources

Dendreon Appoints Richard Ranieri as Senior Vice President of Human Resources
SEATTLE, April 15, 2010 /PRNewswire via COMTEX/ --Dendreon Corporation (Nasdaq: DNDN) today announced that Richard Ranieri has joined the company as senior vice president of human resources, effective April 19, 2010. Mr. Ranieri most recently served as the executive vice president of human resources and administration at Sepracor, Inc.

In his role at Dendreon, Mr. Ranieri will be responsible for overseeing the human resources team, leading the development and implementation of strategies for the recruitment of talent, training, development and growth of employees, and management of compensation and benefits.

"Rich's 20 years of experience managing large global human resource initiatives for commercial health care companies makes him the ideal fit as we transition into a world-class commercial enterprise," said Mitchell H. Gold, MD, president and chief executive officer of Dendreon.

Prior to his position at Sepracor, Mr. Ranieri served as the senior vice president of human resources and chief administrative officer at Neurocrine Biosciences, where he was responsible for managing and directing the human resources, corporate communications, operations and purchasing functions of the company. Before he joined Neurocrine Biosciences, Mr. Ranieri served as senior vice president of human resources at Genencor International, where he managed and directed the organizations global human resources function, liaising closely with senior management and the board of directors to help guide the growth and development of talent for the company. Prior to assuming that role, Mr. Ranieri held several executive positions in human resources, sales management and sales operations at SmithKline Beecham.

Mr. Ranieri received a master's degree from Rider College and a bachelor's degree from Villanova University.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development and commercialization of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule that targets TRPM8 that could be applicable to multiple types of cancer. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

SOURCE Dendreon Corporation
 

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.